PURPOSE: To determine whether simvastatin is able to inhibit inflammation in trinitrobenzene sulfonic acid (TNBS)-induced or oxazalone (OXA)-induced colitis. RESULTS: In the prophylactic protocol, simvastatin dose-dependently suppressed the decrease in body weight and inflammatory grade of TNBS-treated mice. In contrast, in the therapeutic protocol, no significant difference in body weight reduction was observed between simvastatin-treated and control mice. IFN-gamma release from LP cells was significantly suppressed in mice receiving high-dose simvastatin in the prophylactic protocol. In contrast to TNBS colitis, even high-dose prophylactic simvastatin had no suppressive effects on either weight reduction or the inflammatory grade in OXA colitis. CONCLUSION: Our results indicate that simvastatin negatively regulates inflammation in TNBS-induced colitis, but not in OXA-induced colitis. In TNBS-induced colitis, simvastatin suppressed the Th1-polarized immune response. Our findings suggest that simvastatin has potential effects as a therapeutic agent in human inflammatory bowel disease, particularly Crohn's disease.
PURPOSE: To determine whether simvastatin is able to inhibit inflammation in trinitrobenzene sulfonic acid (TNBS)-induced or oxazalone (OXA)-induced colitis. RESULTS: In the prophylactic protocol, simvastatin dose-dependently suppressed the decrease in body weight and inflammatory grade of TNBS-treated mice. In contrast, in the therapeutic protocol, no significant difference in body weight reduction was observed between simvastatin-treated and control mice. IFN-gamma release from LP cells was significantly suppressed in mice receiving high-dose simvastatin in the prophylactic protocol. In contrast to TNBS colitis, even high-dose prophylactic simvastatin had no suppressive effects on either weight reduction or the inflammatory grade in OXAcolitis. CONCLUSION: Our results indicate that simvastatin negatively regulates inflammation in TNBS-induced colitis, but not in OXA-induced colitis. In TNBS-induced colitis, simvastatin suppressed the Th1-polarized immune response. Our findings suggest that simvastatin has potential effects as a therapeutic agent in humaninflammatory bowel disease, particularly Crohn's disease.
Authors: Edward E S Nieuwenhuis; Markus F Neurath; Nadia Corazza; Hideki Iijima; Joanne Trgovcich; Stefan Wirtz; Jonathan Glickman; Dan Bailey; Masaru Yoshida; Peter R Galle; Mitchell Kronenberg; Mark Birkenbach; Richard S Blumberg Journal: Proc Natl Acad Sci U S A Date: 2002-12-13 Impact factor: 11.205
Authors: Meenakshi Arora; Li Chen; Melissa Paglia; Iain Gallagher; Judith E Allen; Yatin M Vyas; Anuradha Ray; Prabir Ray Journal: Proc Natl Acad Sci U S A Date: 2006-05-08 Impact factor: 11.205
Authors: Sawsan Youssef; Olaf Stüve; Juan C Patarroyo; Pedro J Ruiz; Jennifer L Radosevich; Eun Mi Hur; Manuel Bravo; Dennis J Mitchell; Raymond A Sobel; Lawrence Steinman; Scott S Zamvil Journal: Nature Date: 2002-11-07 Impact factor: 49.962
Authors: Makoto Sasaki; Sulaiman Bharwani; Paul Jordan; Takashi Joh; Kenneth Manas; April Warren; Hirohisa Harada; Patsy Carter; John W Elrod; Michael Wolcott; Matthew B Grisham; J Steven Alexander Journal: J Pharmacol Exp Ther Date: 2003-04 Impact factor: 4.030
Authors: Bernard P Leung; Naveed Sattar; Anne Crilly; Morag Prach; David W McCarey; Helen Payne; Rajan Madhok; Carol Campbell; J Alastair Gracie; Foo Y Liew; Iain B McInnes Journal: J Immunol Date: 2003-02-01 Impact factor: 5.422
Authors: David W McCarey; Iain B McInnes; Rajan Madhok; Rosie Hampson; Olga Scherbakov; Ian Ford; Hilary A Capell; Naveed Sattar Journal: Lancet Date: 2004-06-19 Impact factor: 79.321
Authors: Haley A Vecchiarelli; Maria Morena; Catherine M Keenan; Vincent Chiang; Kaitlyn Tan; Min Qiao; Kira Leitl; Alessia Santori; Quentin J Pittman; Keith A Sharkey; Matthew N Hill Journal: Neuropsychopharmacology Date: 2021-01-15 Impact factor: 7.853
Authors: Bruce E Sands; Jean-Frédéric Colombel; Christina Ha; Michel Farnier; Alessandro Armuzzi; Daniel Quirk; Gary S Friedman; Kenneth Kwok; Leonardo Salese; Chinyu Su; Pam R Taub Journal: Inflamm Bowel Dis Date: 2021-05-17 Impact factor: 5.325